CSL LIMITED news, videos and press releases - Page 4
For more news please use our advanced search feature.
CSL LIMITED - More news...
CSL LIMITED - More news...
- Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
- Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022
- CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
- CSL Plasma Opens 300th Plasma Donation Center in United States
- HCmed Reaches Milestone in Immunoglobin Combination Product Development with CSL Behring
- Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day
- Urban League of Philadelphia Names CSL's Elizabeth Walker to Board of Directors
- CSL Plasma to Provide Flu Vaccines to U.S. Plasma Donors
- The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment
- FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience
- Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients
- New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days
- Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge
- CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
- CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
- Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients
- Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
- LF Energy Partners with Sony Computer Science Laboratories to Launch Open-Source Microgrid Project
- LF Energy Partners with Sony Computer Science Laboratories to Launch Open-Source Microgrid Project
- Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients
- Campbell's® Chunky® Teams With NFL Players, GENYOUth And CSL Esports To Tackle Hunger In Schools With The "Chunky® Million Meals Challenge" Presented By Target
- New Harris Poll Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1-INH Deficiency When Choosing an HAE Therapy
- Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
- CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020
- CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease
- CSL Named as One of the World's Best Employers
- CSL's Broad Response to COVID-19 and Advancements across the Company's Strategic Scientific Platforms are the Focus of Annual R&D Day
- Barings Backs ECI's Acquisition of CSL
- U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
